Loading organizations...
Axenya is a São Paulo, Brazil-based healthtech company that provides an AI-driven software and hardware platform for corporate healthcare data integration and chronic disease management. The business operates a B2B2C model, supplying enterprises and health insurers with a digital therapeutics ecosystem that connects patient biometrics from wearable medical devices to predictive analytics tools. The platform helps corporate clients optimize employee health spending, demonstrating a 22 percent year-over-year decrease in total healthcare expenses and a 40 percent reduction in high-risk patient management costs. To support its technology expansion across Latin America, the enterprise has raised capital across multiple financing rounds, including a $12 million Series A and a $6 million seed round. These investments were backed by prominent venture firms Canary, Indicator Capital, Igah Ventures, and Alexia Ventures. Axenya was founded in 2020 by Mariano García-Valiño.
Axenya has raised $15.0M across 2 funding rounds.
Axenya has raised $15.0M in total across 2 funding rounds.
Axenya has raised $15.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 27, 2025 | $12M Series A | Kristian Huber, Thomas Bittar | Zentynel Frontier Investments | Announced |
| Jul 1, 2021 | $3M Seed | — | DGF Investimentos, Igah Ventures | Announced |
Axenya is a São Paulo, Brazil-based health tech company founded in 2020 that builds an AI-driven platform for orchestrating corporate healthcare.[1][2] It connects companies, employees, insurers, and healthcare providers through LifeVault—an interoperable data lake for clinical, operational, and administrative data—and Axenya IQ, a predictive AI and GenAI engine that anticipates risks, suggests interventions, and optimizes care journeys.[1][2] Serving large enterprises, Axenya solves fragmented corporate health management by reducing costs (e.g., 22% year-over-year drop, 50% below-market medical inflation) and improving outcomes for high-risk patients via predictive prevention, especially for chronic conditions like heart rate and blood pressure monitoring.[2][6] In August 2025, it raised $12 million in Series A funding led by Canary and co-led by Indicator Capital, following $6.8 million in prior rounds, to fuel commercial expansion and tech advancements.[1][2]
Axenya was founded in 2020 by Mariano Garcia-Valiño, who serves as CEO, amid Brazil's complex corporate healthcare landscape where traditional brokers fail to integrate stakeholders effectively.[1][2] Garcia-Valiño's vision emerged from recognizing the need for data intelligence to transform systemic inefficiencies, combining cutting-edge AI with a business model that reshapes healthcare delivery.[2] Early traction came from proven client results, such as 1,500 basis points lower loss ratios and 40% expense reductions for high-risk patients, building on prior funding from Patria High Growth, Big_Bets, and Zentynel.[2] The 2025 Series A marked a pivotal moment, validating its approach and enabling scale in Latin America's growing health tech market.[1]
Axenya rides the wave of AI-powered digital health transformation, particularly in managing chronic conditions amid rising corporate healthcare costs in Latin America.[3][6] Timing aligns with post-pandemic demand for predictive prevention and data interoperability, fueled by GenAI advancements and biomarker connectivity.[1][2] Market forces like Brazil's high medical inflation and fragmented systems favor its model, positioning it to influence the ecosystem by lowering barriers for insurers and providers while enabling enterprises to retain talent through better health outcomes.[2] As a leader in LatAm health tech, it exemplifies how regional VCs like Canary and Indicator Capital are backing deep-tech to bridge global AI trends with local needs.[1]
Axenya is poised for rapid scaling post-Series A, prioritizing commercial growth in Brazil and potentially LatAm expansion via strengthened channels and AI enhancements.[1][2] Trends like GenAI maturation, connected health devices, and employer-focused wellness will amplify its edge, especially as chronic care demands grow.[3][6] Its influence may evolve from cost-cutter to ecosystem orchestrator, potentially attracting Series B interest if it sustains 20-50% efficiency gains. This positions Axenya as a benchmark for AI reshaping corporate health, delivering the structural change Garcia-Valiño envisioned from day one.[2]
Axenya has raised $15.0M in total across 2 funding rounds.
Axenya's investors include Kristian Huber, Thomas Bittar, Zentynel Frontier Investments, DGF Investimentos, Igah Ventures.
